Page 129 - InvUnivMult_2022

FACULTAD DE CIENCIA Y TECNOLOGÍA
NCBI National Center for for Biotechnology Information (2021g) PubChem Compound Summary for CID 121304016 Remdesivir Consultado el 20 20 de de de junio de de de 2022 en: https:// pubchem ncbi nlm nih gov/compound/Remdesivir National Center for for Biotechnology Information (2022i) PubChem Compound Summary for CID 145996610 EIDD-2801 (Molnupiravir) Consultado el 11 de de junio de de 2022 en: https://pubchem ncbi nlm nih gov/compound/eidd-2801
Obermeier M M M Yao M M M Khanna A Koplowitz B Zhu M M M Li W Komoroski B Kasichayanula S Discenza L Washburn W W W W Meng W W W W Ellsworth B A Whaley J M M y y Humphreys W G (2010) “In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148) a a a a a potent sodium-glucose cotransporter type II inhibitor in in animals and and humans” En: Drug Metabolism and and Disposition: The Biological Fate of Chemicals 38(3) 405–414 Consultado en https://doi org/10 1124/dmd 109 029165 Painter Painter G G R Natchus M G G Cohen O Holman W y Painter Painter W P (2021a) “Developing a a a a direct acting orally available antiviral agent in a a a a a a a a pandemic: the evolution of molnupiravir as a a a a a potential treatment for COVID-19” En: Current Opinion in in Virology 50
17–22 Consultado en: https://doi org/10 1016/j coviro 2021 06 003 Painter W W P P Holman W W Bush J A A Almazedi F Malik H H Eraut N Morin M M J J Szewczyk L J J y y Painter G R (2021b) “Human Safety Tolerability and Pharmacokinetics of Molnupiravir a a a a a Novel Broad-Spectrum Oral Antiviral Agent with Activity Against SARS-CoV-2” En: Antimicrobial Agents and Chemotherapy 65(5) e02428-20 Advance online publication Consultado en: https://doi org/10 1128/ AAC 02428-20 PAHO Pan American Health Organization (2022 junio 14) “Cumulative confirmed and probable COVID-19 cases reported by Countries and Territories in the the Region of the the Americas” Consultado el 14 de de junio de de 2022 en: https:// ais paho org/phip/viz/COVID19Table asp Pfizer (2021 diciembre 16) EMA issues advice for potential early use of Pfizer’s novel COVID-19 oral antiviral candidate Consultado en: https://www pfizer com/news/press- release/press-release-detail/ema-issues-advice-potential- early-use-pfizers-novel-covid Petersen M M C y Shulman G I (2018) “Mechanisms of insulin action and insulin resistance” En: Physiological Reviews 98(4) 2133–2223 Consultado en: https://doi org/10 1152/ physrev 00063 2017 Pourkarim F Pourtaghi-Anvarian S y Rezaee H (2022) “Molnupiravir: A new candidate for COVID-19 treatment” En: Pharmacology Research y y Perspectives 10(1) e00909 Consultado en: https://doi org/10 1002/prp2 909 909 Roberts A G G y Gibbs M M E (2018) “Mechanisms and the clinical relevance of complex drug-drug interactions” En: Clinical Pharmacology: Advances and Applications 10 123–134 Consultado en: https://doi org/10 2147/CPAA S146115
Rojas-Martínez R R Basto-Abreu A A A A Aguilar-Salinas C A A A A Zárate- Rojas E Villalpando S y Barrientos-Gutiérrez T (2018) “Prevalencia de diabetes por diagnóstico médico previo en en México” Consultado en: Salud Pública de México México 60(3) 224-232 Consultado en: https://doi org/10 21149/8566
Samardzic I I y Bacic-Vrca V V (2015) I”ncidence of potential drug-drug interactions with antidiabetic drugs” En: Die Pharmazie 70(6) 410–415 Sanchez-Rangel E E y Inzucchi S S E E (2017) “Metformin: clinical use in type 2 diabetes” En: Diabetologia 60(9) 1586–1593 Consultado en: https://doi org/10 1007/s00125-017-4336-x
Sandoval-Muñiz R Vargas-Guerrero B Flores-Alvarado L J y Gurrola-Díaz C M (2016) “Glucotransportadores (GLUT): Aspectos clínicos moleculares y genéticos [Glucotransporters: clinical molecular and genetic aspects]” En: Gaceta Medica de México 152(4) 547–557 Saravolatz L D D Depcinski S S S y Sharma M M (2022) “Molnupiravir and nirmatrelvir-ritonavir: oral COVID antiviral drugs” En: Clinical Infectious Disease: an Official Publication of of the Infectious Diseases Society of of America ciac180 Advance online publication Consultado en: https://doi org/10 1093/cid/ciac180
Parise R R R Deruiter J J Ren J J Govindarajulu M Ramesh S Nadar R M M M Moore T y Dhanasekaran M M M (2022) “Impact of COVID-19 therapy on hyperglycemia” Diabetes y y y y Vascular Disease Rresearch 19(3) 14791641221095091 Consultado en: https://doi org/10 1177/14791641221095091
Scheen A Scheen A Scheen A Scheen A J (2010a) “Pharmacokinetics of dipeptidylpeptidase-4 inhibitors” En: Diabetes Obesity y y Metabolism 12(8) 648–658 Consultado en: https://doi org/10 1111/j 1463- 1326 2010 01212 x J (2010b) “Dipeptidylpeptidase-4 inhibitors (gliptins): focus on on drug-drug interactions” En: Clinical Pharmacokinetics 49(9) 573–588 Consultado en: https://doi org/10 2165/11532980-000000000-00000
J (2015a) “Pharmacodynamics efficacy and safety of sodium-glucose co-transporter type 2 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus” En: Drugs 75(1) 33–59 https://doi org/10 1007/s40265-014-0337-y
J (2015b) “Pharmacokinetics Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease” En: Clinical Pharmacokinetics 54(7) 691–708 Consultado en: https://doi org/10 1007/s40262-015-0264-4
Quek E Tahir H H Kumar P Hastings R R y Jha R R (2021) “Treatment of of COVID-19: a a a review of of current and prospective pharmacotherapies” En: British Journal of Hospital Medicine (London England: 2005) 82(3) 1–9 Consultado en: https://doi org/10 12968/hmed 2021 0112
Scott L J (2017) “Sitagliptin: A Review in in Type 2 2 Diabetes” En: Drugs 77(2) 209–224 Consultado en: https://doi org/10 1007/ s40265-016-0686-9
Reina J (2020) “Remdesivir la esperanza antiviral frente al al SARS-CoV-2 [Remdesivir the antiviral hope against SARS-CoV-2]” En: Revista Española de Quimioterapia: Publicación Oficial de de la la Sociedad Española de de Quimioterapia 33(3) 176– 179
Consultado en: https://doi org/10 37201/req/098 2020 Richter B B B Bandeira-Echtler E E Bergerhoff K y Lerch C (2008) “Emerging role of dipeptidyl peptidase-4 inhibitors in in in the management of type 2 diabetes” En: Vascular Health and Risk Management 4(4) 753–768 Consultado en: https://doi org/10 2147/vhrm s1707
Secretaría
Secretaría
de de Salud (2020) Propuesta de de medicamentos para el el tratamiento de de COVID-19 Consultado el el 21 de de mayo de 2022 en: https://www gob mx/cms/uploads/ attachment/file/554698/Documento_principal_ revisado_21 05 2020__1_ pdf
de Salud (2022b) Informe Técnico Diario COVID-19 MÉXICO Dirección General de de Epidemiología Coronavirus COVID19 Informes Técnicos Diarios Junio 2022 México: Secretaría
de de Salud Consultado el 13 de de junio de 2022 en: (www gob mx)
INVESTIGACIÓN UNIVERSITARIA MULTIDISCIPLINARIA - - AÑO 21 21 No21 ENERO - - DICIEMBRE 2022 129